Claims

1. The use of a compound that is seladelpar or a salt thereof in the manufacture of a medicament for treating cholestatic pruritus.

2. The use of claim 1 where the compound is a seladelpar L-lysine salt.

3. The use of claim 2 where the compound is seladelpar L-lysine dihydrate salt.

4. The use of any one of claims 1 to 3 where the compound is to be administered orally.

5. The use of any one of claims 1 to 4 where the amount of the compound is equivalent to between 0.5 mg/day and 50 mg/day of seladelpar.

6. The use of claim 5 where the amount of the compound is equivalent to at least 1 mg/day of seladelpar.

7. The use of claim 5 or 6 where the amount of the compound is equivalent to not more than 25 mg/day of seladelpar.

8. The use of claim 7 where the amount of the compound is equivalent to 2 mg/day, 5 mg/day, or 10 mg/day of seladelpar.

9. The use of claim 8 where the amount of the compound is equivalent to 2 mg/day of seladelpar.

10. The use of claim 8 where the amount of the compound is equivalent to 5 mg/day of seladelpar.

11. The use of claim 8 where the amount of the compound is equivalent to 10 mg/day of seladelpar.

12. The use of any one of claims 1 to 11 where the compound is to be administered once/day.

13. The use of any one of claims 1 to 11 where the compound is to be administered between once/week and every other day.

14. The use of any one of claims 1 to 13 where the cholestatic pruritus is associated with a hepatobiliary disease.

15. The use of claim 14 where the hepatobiliary disease associated with the pruritus is a hepatocellular cholestasis.

16. The use of claim 14 where the hepatobiliary disease associated with the pruritus is a cholangiocellular cholestasis.

17. The use of claim 14 where the hepatobiliary disease associated with the pruritus is an obstructive cholestasis.

18. The use of any one of claims 1 to 13 where the cholestatic pruritus is associated with an intrahepatic cholestatic disease.

19. The use of claim 18 where the intrahepatic cholestatic disease is primary biliary cholangitis, primary sclerosing cholangitis, progressive familial intrahepatic cholestasis, or Alagille syndrome.

20. The use of claim 19 where the cholestatic pruritus is associated with primary biliary cholangitis.

21. The use of claim 19 where the cholestatic pruritus is associated with primary sclerosing cholangitis.

22. The use of claim 19 where the cholestatic pruritus is associated with progressive familial intrahepatic cholestasis.

23. The use of claim 19 where the cholestatic pruritus is associated with Alagille syndrome.

24. The use of any one of claims 1 to 13 where the cholestatic pruritus is associated with the intrahepatic cholestasis of pregnancy.